Adverum Biotechnologies, Inc.

Symbol: ADVM

NASDAQ

9.61

USD

Market price today

  • -0.8302

    P/E Ratio

  • 0.0129

    PEG Ratio

  • 199.47M

    MRK Cap

  • 0.00%

    DIV Yield

Adverum Biotechnologies, Inc. (ADVM) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

-2.49%

Operating Profit Margin

-34.39%

Net Profit Margin

-32.55%

Return on Assets

-0.68%

Return on Equity

-0.99%

Return on Capital Employed

-0.84%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Laurent Fischer
Full-time employees:121
City:Redwood City
Address:800 Saginaw Drive
IPO:2014-07-31
CIK:0001501756

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

General Outlook

When we look at how much money they make before expenses, they keep -2.494% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -34.386%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -32.546%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.677% return, is a testament to Adverum Biotechnologies, Inc.'s adeptness in optimizing resource deployment. Adverum Biotechnologies, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.986%. Furthermore, the proficiency of Adverum Biotechnologies, Inc. in capital utilization is underscored by a remarkable -0.836% return on capital employed.

Stock Prices

Adverum Biotechnologies, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $10.25, while its low point bottomed out at $9.56. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Adverum Biotechnologies, Inc.'s stock market.

Liquidity Ratios

Analyzing ADVM liquidity ratios reveals its financial health of the firm. The current ratio of 412.51% gauges short-term asset coverage for liabilities. The quick ratio (387.44%) assesses immediate liquidity, while the cash ratio (301.04%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio412.51%
Quick Ratio387.44%
Cash Ratio301.04%

Profitability Ratios

ADVM profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -3284.53% underscores its earnings before tax deductions. The effective tax rate stands at 0.91%, revealing its tax efficiency. The net income per EBT, 99.09%, and the EBT per EBIT, 95.52%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -3438.64%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-3284.53%
Effective Tax Rate0.91%
Net Income per EBT99.09%
EBT per EBIT95.52%
EBIT per Revenue-3438.64%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 4.13, it details the span from stock purchase to revenue. The 4 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding387
Days of Payables Outstanding56
Cash Conversion Cycle-56
Payables Turnover6.55
Fixed Asset Turnover0.05
Asset Turnover0.02

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -8.99, and free cash flow per share, -9.07, depict cash generation on a per-share basis. The cash per share value, 9.54, showcases liquidity position. Lastly, the operating cash flow sales ratio, -25.27, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-8.99
Free Cash Flow per Share-9.07
Cash per Share9.54
Operating Cash Flow Sales Ratio-25.27
Free Cash Flow to Operating Cash Flow Ratio1.01
Cash Flow Coverage Ratio-1.21
Short Term Coverage Ratio-8.74
Capital Expenditure Coverage Ratio-112.60
Dividend Paid and Capex Coverage Ratio-112.60

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 43.37%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.90, we discern the balance between debt and equity financing. The long-term debt to capitalization, 43.64%, and total debt to capitalization, 47.34%, ratios shed light on its capital structure. An interest coverage of 103.16 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio43.37%
Debt Equity Ratio0.90
Long Term Debt to Capitalization43.64%
Total Debt to Capitalization47.34%
Interest Coverage103.16
Cash Flow to Debt Ratio-1.21
Company Equity Multiplier2.07

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.36, provides a glimpse into top-line earnings distributed across each share. Net income per share, -11.62, reflects the portion of profit attributed to each share. The book value per share, 8.28, represents the net asset value distributed per share, while the tangible book value per share, 8.28, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.36
Net Income Per Share-11.62
Book Value Per Share8.28
Tangible Book Value Per Share8.28
Shareholders Equity Per Share8.28
Interest Debt Per Share7.44
Capex Per Share-0.08

Growth Ratios

EBIT growth, 21.22%, and operating income growth, 21.22%, offer insights into operational profitability progression. The net income growth, 24.18%, showcases bottom-line expansion, and the EPS growth, 25.37%, measures the growth in earnings per share.

cards.indicatorcards.value
Gross Profit Growth68.69%
EBIT Growth21.22%
Operating Income Growth21.22%
Net Income Growth24.18%
EPS Growth25.37%
EPS Diluted Growth25.37%
Weighted Average Shares Growth1.58%
Weighted Average Shares Diluted Growth1.58%
Operating Cash Flow Growth15.51%
Free Cash Flow Growth23.17%
10-Year Revenue Growth per Share1445.40%
5-Year Revenue Growth per Share1259.46%
10-Year Operating CF Growth per Share-8551.58%
5-Year Operating CF Growth per Share-930.15%
3-Year Operating CF Growth per Share2.74%
10-Year Net Income Growth per Share-4475.86%
5-Year Net Income Growth per Share-882.04%
3-Year Net Income Growth per Share15.80%
10-Year Shareholders Equity Growth per Share78994.73%
5-Year Shareholders Equity Growth per Share152.58%
3-Year Shareholders Equity Growth per Share-83.77%
Asset Growth-43.90%
Book Value per Share Growth-54.73%
Debt Growth-29.74%
R&D Expense Growth-21.96%
SGA Expenses Growth-23.48%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 75,956,472, captures the company's total value, considering both debt and equity. Income quality, 0.78, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 13.87, gauges operational efficiency, while the research and development to revenue, 2152.11%, highlights investment in innovation.

cards.indicatorcards.value
Enterprise Value75,956,472
Income Quality0.78
Sales General and Administrative to Revenue13.87
Research and Development to Revenue2152.11%
Capex to Operating Cash Flow0.88%
Capex to Revenue-22.44%
Capex to Depreciation-14.32%
Stock-Based Compensation to Revenue488.03%
Graham Number46.53
Return on Tangible Assets-67.72%
Graham Net Net0.69
Working Capital77,859,000
Tangible Asset Value83,469,000
Net Current Asset Value13,232,000
Invested Capital1
Average Payables2,079,500
Days Payables Outstanding124
ROIC-77.39%
ROE-1.40%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.17, and the price to book ratio, 1.17, reflect the market's valuation relative to the company's book value. The price to sales ratio, 55.41, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -2.17, and price to operating cash flows, -1.07, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.17
Price to Book Ratio1.17
Price to Sales Ratio55.41
Price Cash Flow Ratio-1.07
Price Earnings to Growth Ratio0.01
Enterprise Value Multiple-1.69
Price Fair Value1.17
Price to Operating Cash Flow Ratio-1.07
Price to Free Cash Flows Ratio-2.17
Price to Tangible Book Ratio0.91
Enterprise Value to Sales21.10
Enterprise Value Over EBITDA-0.64
EV to Operating Cash Flow-0.83
Earnings Yield-154.33%
Free Cash Flow Yield-121.35%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Adverum Biotechnologies, Inc. (ADVM) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.830 in 2024.

What is the ticker symbol of Adverum Biotechnologies, Inc. stock?

The ticker symbol of Adverum Biotechnologies, Inc. stock is ADVM.

What is company IPO date?

IPO date of Adverum Biotechnologies, Inc. is 2014-07-31.

What is company current share price?

Current share price is 9.610 USD.

What is stock market cap today?

The market cap of stock today is 199472848.000.

What is PEG ratio in 2024?

The current 0.013 is 0.013 in 2024.

What is the number of employees in 2024?

In 2024 the company has 121.